KR20020060298A - 혼합 백신의 제조 방법 - Google Patents
혼합 백신의 제조 방법 Download PDFInfo
- Publication number
- KR20020060298A KR20020060298A KR1020010001290A KR20010001290A KR20020060298A KR 20020060298 A KR20020060298 A KR 20020060298A KR 1020010001290 A KR1020010001290 A KR 1020010001290A KR 20010001290 A KR20010001290 A KR 20010001290A KR 20020060298 A KR20020060298 A KR 20020060298A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- vaccine
- mixed
- hepatitis
- pertussis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (10)
- 디프테리아, 파상풍, 백일해 및 B형 간염 등 소아기의 예방하여야 할 각 질병에 대한 각각의 예방 항원을 수산화 알루미늄 겔 형태의 흡착제에 독립적으로 흡착시키는 단계 및 흡착 후 상기 흡착제에 흡착된 각각의 예방 항원을 혼합하는 단계를 포함하는, 디프테리아, 파상풍, 백일해 및 B형 간염 등 소아기의 예방하여야 할 질병을 동시에 예방하기 위한 혼합백신의 제조방법
- 제1항에 있어서, 혼합 백신 제제 후의 수산화알루미늄 겔의 알루미늄 이온 농도가 0.5 ∼ 1.25 mg/ml 범위인 것을 특징으로 하는, 혼합백신의 제조방법.
- 제1항 또는 제2항에 있어서, 상기 흡착제에 흡착된 각각의 예방 항원을 혼합한 후에, 0.5 ∼ 1.25 mg/ml 의 알루미늄 이온의 농도 범위를 넘지 않는 범위에서 여분의 흡착제를 첨가하는 단계를 추가로 포함하는, 혼합백신의 제조방법.
- 제1항에 있어서, 상기 B형 간염 항원으로서 유전 공학적으로 제조된 B형 간염 표면 항원을 소아 1회 투여량 기준 5 ~ 10 ug 의 양으로 혼합하는 것을 특징으로 하는,혼합백신의 제조방법.
- 제4항에 있어서, 폴리소베이트 20, 폴리소베이트 80, 트리톤 X-100 과 같은 중성 계면활성제를 첨가하는 단계를 추가로 포함하는, 혼합백신의 제조방법.
- 제4항에 있어서, B형 간염 항원을 흡착제와 2∼8℃에서 3∼20 시간동안 교반하여 숙성시켜 흡착시키는 것을 특징으로 하는, 혼합백신의 제조방법.
- 제1항에 있어서, 상기 디프테리아 항원으로서 무독화한 디프테리아 독소를 소아 1회 투여량 기준 10∼25 Lf의 양으로 혼합하는 것을 특징으로 하는, 혼합백신의 제조방법.
- 제1항에 있어서, 상기 파상풍 항원으로서 무독화한 파상풍 독소를 소아 1회 투여량 기준 1∼5 Lf의 양으로 혼합하는 것을 특징으로 하는, 혼합백신의 제조방법.
- 제1항에 있어서, 상기 백일해 항원으로서, 정제된 다종의 항원 단백질을 소아 1회 투여량 기준 20 ㎍PN 이하의 양으로 혼합하거나 또는 전세포성 백일해 항원을 소아 1회 투여량 기준 20 OE 이하의 양으로 혼합하는 것을 특징으로 하는,혼합백신의 제조방법.
- 제9항에 있어서, 정제된 다종의 항원 단백질이, 무독화한 백일해 독소 및 사상 혈구 응집소 항원을 포함하는 것을 특징으로 하는, 혼합백신의 제조방법.
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0001290A KR100401423B1 (ko) | 2001-01-10 | 2001-01-10 | 혼합 백신의 제조 방법 |
MYPI20020056A MY143688A (en) | 2001-01-10 | 2002-01-08 | Manufacturing method of combined vaccine |
MXPA03006154A MXPA03006154A (es) | 2001-01-10 | 2002-01-09 | Metodo de fabricacion de vacuna combinada. |
JP2002555838A JP3977257B2 (ja) | 2001-01-10 | 2002-01-09 | 混合ワクチンの製造方法 |
SI200230610T SI1349572T1 (sl) | 2001-01-10 | 2002-01-09 | Postopek izdelave kombinirane vakcine |
DE60222529T DE60222529T2 (de) | 2001-01-10 | 2002-01-09 | Herstellungsverfahren für kombinationsimpfstoffe |
CNB028035933A CN1228086C (zh) | 2001-01-10 | 2002-01-09 | 联合疫苗的制备方法 |
AT02729589T ATE373485T1 (de) | 2001-01-10 | 2002-01-09 | Herstellungsverfahren für kombinationsimpfstoffe |
EP02729589A EP1349572B1 (en) | 2001-01-10 | 2002-01-09 | Manufacturing method of combined vaccine |
US10/465,930 US20040048336A1 (en) | 2001-01-10 | 2002-01-09 | Manufacturing method of combined vaccine |
CA2434421A CA2434421C (en) | 2001-01-10 | 2002-01-09 | Manufacturing method of combined vaccine |
ARP020100060A AR032391A1 (es) | 2001-01-10 | 2002-01-09 | Metodo de elaboracion de vacuna combinada y producto resultante |
PE2002000008A PE20020758A1 (es) | 2001-01-10 | 2002-01-09 | Metodo de fabricacion de vacuna combinada |
PL369433A PL211005B1 (pl) | 2001-01-10 | 2002-01-09 | Sposób wytwarzania szczepionki zespolonej |
PCT/KR2002/000034 WO2002055105A1 (en) | 2001-01-10 | 2002-01-09 | Manufacturing method of combined vaccine |
UY27118A UY27118A1 (es) | 2001-01-10 | 2002-01-09 | Método de producción de vacuna combinada |
AU2002219693A AU2002219693B2 (en) | 2001-01-10 | 2002-01-09 | Manufacturing method of combined vaccine |
ES02729589T ES2291466T3 (es) | 2001-01-10 | 2002-01-09 | Procedimiento de fabricacion de vacuna mixta. |
RU2003124660/15A RU2264226C2 (ru) | 2001-01-10 | 2002-01-09 | Способ производства комбинированной вакцины |
BR0206391-3A BR0206391A (pt) | 2001-01-10 | 2002-01-09 | Método para a fabricação de uma vacina combinada |
IL15679103A IL156791A0 (en) | 2001-01-10 | 2003-01-09 | Manufacturing method of combined vaccine |
ZA200305072A ZA200305072B (en) | 2001-01-10 | 2003-06-30 | Manufacturing method of combined vaccine. |
US12/407,445 US20090181050A1 (en) | 2001-01-10 | 2009-03-19 | Manufacturing Method of Combined Vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0001290A KR100401423B1 (ko) | 2001-01-10 | 2001-01-10 | 혼합 백신의 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020060298A true KR20020060298A (ko) | 2002-07-18 |
KR100401423B1 KR100401423B1 (ko) | 2003-10-17 |
Family
ID=19704448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0001290A KR100401423B1 (ko) | 2001-01-10 | 2001-01-10 | 혼합 백신의 제조 방법 |
Country Status (21)
Country | Link |
---|---|
US (2) | US20040048336A1 (ko) |
EP (1) | EP1349572B1 (ko) |
JP (1) | JP3977257B2 (ko) |
KR (1) | KR100401423B1 (ko) |
CN (1) | CN1228086C (ko) |
AR (1) | AR032391A1 (ko) |
AT (1) | ATE373485T1 (ko) |
AU (1) | AU2002219693B2 (ko) |
BR (1) | BR0206391A (ko) |
CA (1) | CA2434421C (ko) |
DE (1) | DE60222529T2 (ko) |
ES (1) | ES2291466T3 (ko) |
IL (1) | IL156791A0 (ko) |
MX (1) | MXPA03006154A (ko) |
MY (1) | MY143688A (ko) |
PE (1) | PE20020758A1 (ko) |
PL (1) | PL211005B1 (ko) |
RU (1) | RU2264226C2 (ko) |
UY (1) | UY27118A1 (ko) |
WO (1) | WO2002055105A1 (ko) |
ZA (1) | ZA200305072B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022114921A1 (ko) * | 2020-11-30 | 2022-06-02 | 주식회사 엘지화학 | 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69319728T2 (de) | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
CA2654014A1 (en) * | 2006-05-31 | 2007-12-06 | Silvio Buzzi | Pharmaceutical use of protein molecules immunologically correlated to diphtheria toxin |
GB0616306D0 (en) * | 2006-08-16 | 2006-09-27 | Novartis Ag | Vaccines |
PT2097102E (pt) * | 2006-09-07 | 2012-08-03 | Glaxosmithkline Biolog Sa | Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus |
GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
CN102363041A (zh) * | 2011-11-17 | 2012-02-29 | 成都欧林生物科技股份有限公司 | 不含防腐剂疫苗的制作工艺 |
KR101518473B1 (ko) | 2013-03-14 | 2015-05-07 | (주)바이오인디스트 | 애완견의 바이러스성 전염병 예방 및 치료용 복합 난황 항체 조성물 및 그 제조방법 |
AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
AR102547A1 (es) * | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU188847B (en) * | 1983-02-22 | 1986-05-28 | Human Oltoanyagtermeloe Es Kutato Intezet,Hu | Process for producing liophylized combined vaccines |
CA1213234A (en) * | 1983-03-30 | 1986-10-28 | Akihiro Ginnaga | Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine |
US4649192A (en) * | 1985-05-30 | 1987-03-10 | Smith Kline-Rit | Method for the isolation and purification of hepatitis B surface antigen using polysorbate |
EP0251575B2 (en) * | 1986-06-17 | 2002-11-13 | Chiron Corporation | Hepatitis delta diagnostics and vaccines, their preparation and use |
JPH085804B2 (ja) * | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | A型及びb型肝炎混合アジュバントワクチン |
EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
DE69319728T2 (de) * | 1992-05-23 | 1999-02-04 | Smithkline Beecham Biolog | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten |
US6372225B1 (en) * | 1996-03-23 | 2002-04-16 | The Research Foundation Of Microbial Diseases Of Osaka University | Tetanus toxin functional fragment antigen and tetanus vaccine |
GB9611501D0 (en) * | 1996-06-03 | 1996-08-07 | Smithkline Beecham Biolog | Vaccine compositions |
CA2259415A1 (en) * | 1996-07-02 | 1998-01-08 | Connaught Laboratories Limited | Multivalent dtp-polio vaccines |
GB9623233D0 (en) * | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
BR9714980A (pt) * | 1997-09-15 | 2001-11-06 | Pasteur Merieux Msd | Vacinas multivalentes |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
-
2001
- 2001-01-10 KR KR10-2001-0001290A patent/KR100401423B1/ko active IP Right Grant
-
2002
- 2002-01-08 MY MYPI20020056A patent/MY143688A/en unknown
- 2002-01-09 AR ARP020100060A patent/AR032391A1/es unknown
- 2002-01-09 AU AU2002219693A patent/AU2002219693B2/en not_active Ceased
- 2002-01-09 BR BR0206391-3A patent/BR0206391A/pt active Search and Examination
- 2002-01-09 CN CNB028035933A patent/CN1228086C/zh not_active Expired - Fee Related
- 2002-01-09 ES ES02729589T patent/ES2291466T3/es not_active Expired - Lifetime
- 2002-01-09 US US10/465,930 patent/US20040048336A1/en not_active Abandoned
- 2002-01-09 MX MXPA03006154A patent/MXPA03006154A/es active IP Right Grant
- 2002-01-09 PL PL369433A patent/PL211005B1/pl not_active IP Right Cessation
- 2002-01-09 DE DE60222529T patent/DE60222529T2/de not_active Revoked
- 2002-01-09 UY UY27118A patent/UY27118A1/es not_active IP Right Cessation
- 2002-01-09 EP EP02729589A patent/EP1349572B1/en not_active Revoked
- 2002-01-09 WO PCT/KR2002/000034 patent/WO2002055105A1/en active IP Right Grant
- 2002-01-09 RU RU2003124660/15A patent/RU2264226C2/ru active
- 2002-01-09 CA CA2434421A patent/CA2434421C/en not_active Expired - Fee Related
- 2002-01-09 AT AT02729589T patent/ATE373485T1/de not_active IP Right Cessation
- 2002-01-09 JP JP2002555838A patent/JP3977257B2/ja not_active Expired - Fee Related
- 2002-01-09 PE PE2002000008A patent/PE20020758A1/es active IP Right Grant
-
2003
- 2003-01-09 IL IL15679103A patent/IL156791A0/xx not_active IP Right Cessation
- 2003-06-30 ZA ZA200305072A patent/ZA200305072B/en unknown
-
2009
- 2009-03-19 US US12/407,445 patent/US20090181050A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022114921A1 (ko) * | 2020-11-30 | 2022-06-02 | 주식회사 엘지화학 | 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법 |
Also Published As
Publication number | Publication date |
---|---|
AR032391A1 (es) | 2003-11-05 |
UY27118A1 (es) | 2002-08-30 |
ZA200305072B (en) | 2003-09-17 |
CA2434421A1 (en) | 2002-07-18 |
RU2264226C2 (ru) | 2005-11-20 |
AU2002219693B2 (en) | 2006-03-16 |
DE60222529T2 (de) | 2008-06-19 |
US20040048336A1 (en) | 2004-03-11 |
DE60222529D1 (de) | 2007-10-31 |
MXPA03006154A (es) | 2003-09-16 |
ATE373485T1 (de) | 2007-10-15 |
PL369433A1 (en) | 2005-04-18 |
JP2004517866A (ja) | 2004-06-17 |
EP1349572A1 (en) | 2003-10-08 |
PE20020758A1 (es) | 2002-08-29 |
BR0206391A (pt) | 2004-07-27 |
CA2434421C (en) | 2012-02-21 |
EP1349572B1 (en) | 2007-09-19 |
EP1349572A4 (en) | 2004-09-15 |
MY143688A (en) | 2011-06-30 |
PL211005B1 (pl) | 2012-03-30 |
CN1484531A (zh) | 2004-03-24 |
RU2003124660A (ru) | 2005-01-10 |
CN1228086C (zh) | 2005-11-23 |
ES2291466T3 (es) | 2008-03-01 |
US20090181050A1 (en) | 2009-07-16 |
JP3977257B2 (ja) | 2007-09-19 |
KR100401423B1 (ko) | 2003-10-17 |
IL156791A0 (en) | 2004-02-08 |
WO2002055105A1 (en) | 2002-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2194531C2 (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины | |
KR100401423B1 (ko) | 혼합 백신의 제조 방법 | |
WO2016155581A1 (zh) | 一种分离纯化的无细胞百白破-b型流感嗜血杆菌-A群C群脑膜炎球菌联合疫苗及其制备方法 | |
CA2220063C (en) | Acellular pertussis vaccines and methods of preparation thereof | |
JP4980868B2 (ja) | 非細胞性百日咳ワクチンおよびその製造方法 | |
JPH0231689A (ja) | 百日咳トキシンの精製法 | |
MXPA97008481A (es) | Vacunas acelulares de pertussis y metodos de preparacion de las mismas | |
JPH05506649A (ja) | 百日咳菌外膜蛋白質の精製方法 | |
AU641711B2 (en) | Process for purification of a 69 000 dalton antigenetic protein from bordetella pertussis | |
RU2447898C2 (ru) | Вакцина ipv-dpt | |
AU2002219693A1 (en) | Manufacturing method of combined vaccine | |
US8574589B2 (en) | Antigen purification process for pertactin antigen | |
Schmidt et al. | Physical and immunologic properties of rubella antigens | |
Cryz Jr et al. | Effect of formalin toxoiding on Pseudomonas aeruginosa toxin A: biological, chemical, and immunochemical studies | |
JPH07300427A (ja) | 各ワクチン成分の免疫原性を増強した併用小児ワクチン | |
BR112014017416B1 (pt) | Processo de preparação de uma combinação vacinal contendo pelo menos dois antígenos capazes de se adsorverem sobre o óxi-hidróxido de alumínio e composição vacinal | |
EP2592137A1 (en) | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use | |
WO2024029469A1 (ja) | 不活化SARS-CoV-2ワクチンの製造方法、及び不活化SARS-CoV-2ワクチン、並びにSARS-CoV-2又は不活化SARS-CoV-2の精製方法、及びSARS-CoV-2抗原組成物又は不活化SARS-CoV-2抗原組成物 | |
US20100112009A1 (en) | Acellular antibordetella vaccine | |
MXPA99000184A (es) | Vacunas multivalentes de dtp-polio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130612 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140630 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20150618 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20160607 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20180619 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20190625 Year of fee payment: 17 |